VXRT - Vaxart Inc
IEX Last Trade
0.8736
0.022 2.473%
Share volume: 1,600,564
Last Updated: Fri 30 Aug 2024 09:59:51 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.85
0.02
2.54%
Fundamental analysis
12%
Profitability
0%
Dept financing
8%
Liquidity
69%
Performance
10%
Performance
5 Days
-8.51%
1 Month
30.13%
3 Months
6.51%
6 Months
-33.06%
1 Year
7.69%
2 Year
-71.01%
Key data
Stock price
$0.87
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.52 - $1.54
52 WEEK CHANGE
$0.04
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO:
Region: US
Website: vaxart.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: vaxart.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
since its founding in 2004, vaxart has pursued a vision of advancing vaccines—to make them as tablets rather than injections. the company’s proprietary oral vaccine delivery platform is suitable to deliver any recombinant vaccine, positioning vaxart to introduce oral forms of multiple vaccines in the rapidly growing global vaccines market.
Recent news